Unless briefing docs are very positive, that's unlikely. More often than not, the share price drops upon the release of briefing docs. The sole purpose of the documents is to address any concerns with the drug, so investors typically see such things as a negative, even if they shouldn't. In the case of Ampligen, it's a really tough call at this point on whether or not the AdCom will recommend it. Its history does not lend itself to that, but the patient advocacy and FDASIA may outweigh that.
News 
Market Data 
Discover 
